US 9663569
Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 9663569 (Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases) held by The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center
- Grant date
- Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K31/519, A61K39/3955